Nufarm Limited (NUFMF)
| Market Cap | 820.38M +47.7% |
| Revenue (ttm) | 2.30B -1.5% |
| Net Income | -122.10M |
| EPS | -0.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 22.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 850 |
| Open | 2.225 |
| Previous Close | 2.550 |
| Day's Range | 2.225 - 2.225 |
| 52-Week Range | 0.992 - 2.550 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2026 |
About Nufarm
Nufarm Limited, together with its subsidiaries, develops, manufactures, and sells crop protection solutions and seed technologies in Europe, the Middle East, Africa, North America, and the Asia Pacific. The company operates through Crop Protection and Seed Technologies segments. The company offers herbicides, insecticides, and fungicides that help growers protect crops against weeds, pests, and diseases. It also operates base seeds, bioenergy, omega-3 and seed treatment platforms, as well as sells seeds and oil-based products. It also focuses o... [Read more]
Financial Performance
In fiscal year 2025, Nufarm's revenue was 3.44 billion, an increase of 2.91% compared to the previous year's 3.35 billion. Losses were -186.98 million, 621.1% more than in 2024.
Financial numbers in AUD Financial StatementsNews
OTC Markets Group Welcomes Nufarm Limited to OTCQX
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Nufarm Limited (AS...
Nufarm Transcript: Life Sciences Virtual Investor Forum
Management highlighted strong H1 FY 2026 results, driven by a shift to higher-margin products, improved cash flow, and disciplined capital allocation. Strategic priorities include cost savings, portfolio rationalization, and growth in hybrid seeds and emerging platforms, with a focus on sustaining positive free cash flow and margin expansion.
Nufarm upgraded to Buy from Hold at Jefferies
Jefferies upgraded Nufarm (NUFMF) to Buy from Hold with a price target of A$3.50, up from A$2.66, following the confirmation of a cyclical inflection in Crop Protection and Seeds. The…
Nufarm upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Nufarm (NUFMF) to Outperform from Sector Perform with a price target of A$3.60, up from A$3.40. The revised capital-efficiency focus on margins over volumes, cost reduction progra...
Nufarm Earnings Call Transcript: H1 2026
First half saw 18% EBITDA and 35% NPAT growth year-over-year, with improved margins and cash flow, reduced leverage, and strong segment performance in Europe and Hybrid Seeds. Full-year outlook reaffirmed for strong EBITDA growth, lower leverage, and positive free cash flow.
Nufarm Quarterly report: H1 2026
Nufarm has published its H1 2026 quarterly earnings report on May 26, 2026.
Nufarm Earnings release: H1 2026
Nufarm released its H1 2026 earnings on May 26, 2026, summarizing the period's financial results.
Nufarm Slides: H1 2026
Nufarm has posted slides in relation to its H1 2026 quarterly earnings report, which was published on May 26, 2026.
Nufarm Transcript: AGM 2026
The meeting reviewed a disappointing FY 2025 statutory loss, but highlighted strong underlying crop protection performance and strategic repositioning of the seeds business. No dividend was declared, and a new CEO was introduced. All resolutions received strong shareholder support.
Nufarm Earnings Call Transcript: H2 2025
Revenue grew 3% year-on-year with strong Crop Protection performance and improved margins, but a statutory loss of AUD 165 million was recorded due to non-cash items from Seed Technologies. FY2026 outlook is for EBITDA growth, lower leverage, and positive free cash flow.
Nufarm Annual report: H2 2025
Nufarm has published its H2 2025 annual report on November 18, 2025.
Nufarm Slides: H2 2025
Nufarm has posted slides in relation to its H2 2025 quarterly earnings report, which was published on November 18, 2025.
Nufarm Earnings release: H2 2025
Nufarm released its H2 2025 earnings on November 18, 2025, summarizing the period's financial results.
Nufarm Earnings Call Transcript: H1 2025
First half 2025 saw revenue growth and strong crop protection recovery, but Omega-3 price collapse led to a significant write-down and margin pressure. Leverage increased to 4.5x EBITDA, prompting a focus on deleveraging, cost savings, and a review of Seed Technologies' capital structure.
Nufarm Quarterly report: H1 2025
Nufarm has published its H1 2025 quarterly earnings report on May 20, 2025.
Nufarm Slides: H1 2025
Nufarm has posted slides in relation to its H1 2025 quarterly earnings report, which was published on May 20, 2025.
Nufarm Earnings release: H1 2025
Nufarm released its H1 2025 earnings on May 20, 2025, summarizing the period's financial results.
Nufarm Transcript: AGM 2025
The AGM highlighted a challenging FY24 with lower earnings due to industry pressures, but showcased progress in innovation, cost savings, and working capital efficiency. Shareholders expressed concerns about share price, dividends, and governance, with the board emphasizing alignment of incentives and strategic growth initiatives.
Nufarm Earnings Call Transcript: H2 2024
FY24 saw lower earnings and revenue amid industry headwinds, but strong cost and working capital management led to a 25% reduction in net debt. New product launches and growth in Omega-3 and biofuels platforms support a more positive outlook for FY25, with targeted cost savings and inventory reductions.
Nufarm Annual report: H2 2024
Nufarm has published its H2 2024 annual report on November 13, 2024.
Nufarm Slides: H2 2024
Nufarm has posted slides in relation to its H2 2024 quarterly earnings report, which was published on November 13, 2024.
Nufarm Earnings release: H2 2024
Nufarm released its H2 2024 earnings on November 13, 2024, summarizing the period's financial results.
Nufarm downgraded to Sell from Neutral at Citi
Citi downgraded Nufarm to Sell from Neutral with a A$3.65 price target. The analyst says competition is likely to remain heightened given the industry is coming off a period of…
Nufarm downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Nufarm to Neutral from Overweight with a price target of A$5.50, down from A$6. The company repotted softer than expected first half results driven by depressed pricing in…